Ingevity Corporation NGVT R2KR3K
Company Overview
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products for use in gasoline vapor emission control systems in cars, trucks, motorcycles, and boats. This segment also produces other activated carbon products for food, water, beverage, and chemical purification applications. The Performance Chemicals segment consists of road technologies and industrial specialties. This segment's products are used in pavement construction, pavement preservation, pavement reconstruction and recycling, road markings, agrochemical dispersants, lubricants, certain adhesives, rubber, and other industrial uses. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers for use in coatings, resins, elastomers, adhesives, bioplastics, and medical devices. It serves automotive parts manufacturers through sales representatives, third-party sales representatives, and distributors. The company was formerly known as WestRock Company, Specialty Chemicals Business and changed its name to Ingevity Corporation in September 2015. Ingevity Corporation was founded in 1964 and is headquartered in North Charleston, South Carolina.
Why Investors Should Care
Generates a return on equity of 30.1%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 32.0%.
Operating margin of 29.9% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.17B (-2.7% YoY); net profit $-167.10M.
- Trailing 12 Months Year-on-year growth — revenue -5.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 1.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.10% |
| 1 Year: | -5.20% |
Stock Price Performance
| 1 Year: | +27.10% |
| 6 Months: | +8.61% |
| 3 Months: | +6.89% |
| 1 Month: | -8.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)45.66 · Neutral
P/E of 99.35 is above the sector median of 22.37 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 30.1%.
- Healthy ROCE of 32.0%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 99.3.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Basic Materials).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NGVT Ingevity Corporation R2KR3K | 70.54 | 99.35 | $2.43B | 0.00% | 31.97% | 30.07% | 1.10% | - |
| 2 | LIN Linde plc NDXSPXR3K | 477.57 | 30.83 | $220.15B | 1.31% | 12.46% | 18.40% | 13.90% | 18.47% |
| 3 | SCCO Southern Copper Corporation R3K | 198.76 | 29.49 | $165.83B | 2.28% | 36.40% | 49.90% | 8.32% | 3.80% |
| 4 | NEM Newmont Corporation SPXR3K | 128.09 | 16.15 | $134.97B | 0.99% | - | 25.91% | 6.53% | 20.15% |
| 5 | AEM Agnico Eagle Mines Limited | 204.73 | 17.53 | $103.67B | 1.01% | 19.78% | 22.97% | 27.53% | 88.11% |
| 6 | FCX Freeport-McMoRan Inc. SPXR3K | 72.73 | 35.65 | $101.82B | 0.88% | 12.50% | 14.75% | 1.35% | -1.26% |
| 7 | SHW The Sherwin-Williams Company SPXR3K | 333.71 | 30.81 | $81.01B | 0.88% | 21.93% | 65.12% | 6.18% | 8.26% |
| 8 | ECL Ecolab Inc. SPXR3K | 279.28 | 37.49 | $78.29B | 1.03% | 15.10% | 21.96% | 6.55% | 9.74% |
| 9 | B Barrick Mining Corporation | 44.75 | 10.31 | $74.98B | 1.60% | 16.65% | 25.18% | 15.47% | 126.10% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 218.50M | 260.30M | 264.10M | 229.50M | 235.20M | 308.60M | 311.20M | 278.60M | 276.80M | 352.80M | 359.90M | 303.40M | 288.20M | 270.60M | 331.70M | 325.60M | 320.30M | 358.40M | 376.80M | 382.80M | 419.90M | 482.00M | 392.60M | 481.80M | 446.00M | 340.10M | 390.60M | 333.80M | 247.90M | 365.10M | 333.10M | 258.00M | 314.10M |
| Gross Profit | 82.10M | 76.90M | 49.30M | 63.00M | 74.70M | 80.40M | 56.30M | 70.70M | 89.80M | 93.20M | 75.30M | 85.10M | 115.50M | 118.60M | 97.60M | 97.10M | 134.40M | 139.50M | 111.00M | 114.60M | 83.90M | 139.60M | 127.40M | 126.20M | 139.80M | 141.80M | 137.80M | 150.60M | 176.30M | 130.40M | 153.00M | 129.00M | 99.70M | 123.20M | 131.60M | 111.90M | 137.90M | 133.90M | 116.40M | 139.00M |
| Operating Income | 52.40M | 50.70M | - | 39.30M | 49.20M | 49.50M | - | 39.90M | 57.10M | 62.70M | - | 67.10M | 89.40M | 90.70M | - | 83.50M | 108.30M | 114.00M | - | 92.20M | 67.20M | 127.60M | - | 105.40M | 117.70M | 119.50M | 119.00M | 121.10M | 138.20M | 103.90M | 120.70M | 110.40M | 76.90M | 101.30M | 110.20M | - | - | - | - | - |
| Net Income | 25.30M | 23.80M | 8.60M | 9.20M | 24.10M | -7.20M | 9.10M | 19.00M | 32.10M | 33.80M | 41.60M | 30.80M | 46.70M | 49.50M | 42.10M | 22.70M | 56.80M | 59.90M | 44.30M | 45.30M | 20.20M | 69.90M | - | 48.70M | 44.30M | -4.20M | 60.80M | 59.80M | 75.40M | 50.70M | 35.50M | 25.20M | -56.00M | -283.70M | -107.20M | 20.50M | -146.50M | 43.50M | 59.80M | 35.30M |
| Diluted EPS | 0.60 | 0.57 | 0.20 | 0.22 | 0.57 | -0.17 | 0.22 | 0.45 | 0.76 | 0.79 | 0.97 | 0.72 | 1.10 | 1.16 | 0.99 | 0.54 | 1.34 | 1.41 | 1.05 | 1.08 | 0.49 | 1.69 | 1.11 | 1.20 | 1.10 | -0.11 | 1.55 | 1.54 | 1.98 | 1.35 | 0.97 | 0.69 | -1.54 | -7.81 | -2.94 | 0.56 | -4.02 | 1.18 | 1.66 | 1.00 |
| R&D Expense | - | - | - | 4.60M | 4.60M | 3.90M | - | 5.10M | 4.70M | 4.80M | - | 5.00M | 5.30M | 5.60M | - | 5.10M | 5.00M | 4.90M | - | 6.20M | 5.40M | 5.20M | - | 6.60M | 5.90M | 6.80M | 7.30M | 8.20M | 7.60M | 8.80M | 8.00M | 7.80M | 6.80M | 7.30M | 6.20M | 7.00M | 7.80M | 7.00M | 6.70M | 6.10M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04B | 958.30M | 908.30M | 972.40M | 1.13B | 1.29B | 1.22B | 1.39B | 1.67B | 1.22B | 1.20B | 1.17B |
| Gross Profit | 318.50M | 275.40M | 274.40M | 329.00M | 416.80M | 482.00M | 465.50M | 512.80M | 570.10M | 445.00M | 464.80M | 461.50M |
| Operating Income | 213.30M | 166.30M | 163.60M | 242.70M | 320.50M | 396.90M | 397.90M | 422.20M | 452.60M | 423.20M | 425.90M | 418.70M |
| Net Income | 129.00M | 79.70M | 35.20M | 126.50M | 169.10M | 183.70M | 181.40M | 118.10M | 211.60M | -5.40M | -430.30M | -167.10M |
| Diluted EPS | 3.06 | 1.89 | 0.83 | 2.97 | 3.97 | 4.35 | 4.37 | 2.95 | 5.50 | -0.15 | -11.85 | -4.61 |
| R&D Expense | 7.80M | 17.40M | 17.60M | 19.80M | 21.50M | 19.70M | 22.60M | 26.30M | 30.30M | 25.40M | 24.50M | 28.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 717.30M | 778.70M | 832.80M | 929.60M | 1.32B | 2.14B | 2.33B | 2.47B | 2.74B | 2.62B | 2.02B | 1.65B |
| Total Equity | 326.30M | 416.60M | 513.60M | 127.00M | 263.90M | 338.70M | 530.80M | 642.10M | 673.80M | 698.30M | 631.40M | 195.20M | 29.70M |
| Cash & Equivalents | 11.50M | 19.90M | 32.00M | 30.50M | 87.90M | 77.50M | 56.50M | 257.70M | 275.40M | 76.70M | 95.90M | 68.00M | 78.10M |
| Total Liabilities | - | - | 261.30M | 698.20M | 651.70M | 976.50M | 1.61B | 1.69B | 1.80B | 2.04B | 1.99B | 1.83B | 1.62B |
| Current Liabilities | - | - | 99.80M | 136.90M | 153.20M | 183.30M | 215.50M | 223.40M | 268.90M | 303.50M | 362.90M | 264.10M | 341.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 138.50M | 72.20M | 127.90M | 174.30M | 252.00M | 275.70M | 352.40M | 293.30M | 313.40M | 205.10M | 128.60M | 331.20M |
| Investing Cash Flow | -96.80M | -89.30M | -126.40M | -58.60M | -414.40M | -658.30M | -110.60M | -138.60M | -551.90M | -77.30M | -79.50M | -57.50M |
| Financing Cash Flow | -31.70M | 27.00M | -3.40M | -57.80M | 153.70M | 369.20M | -50.20M | -133.10M | 48.10M | -99.90M | -70.20M | -252.20M |
| Capital Expenditure | - | - | - | - | -93.90M | -114.80M | -82.10M | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | 158.10M | 160.90M | 270.30M | - | - | - | - | - |
| Share Buybacks | - | 0 | 0 | 6.60M | 47.40M | 6.40M | 88.00M | 109.40M | 145.20M | 92.10M | 0 | 56.30M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 30.8% | 28.7% | 30.2% | 33.8% | 36.8% | 37.3% | 38.3% | 36.9% | 34.2% | 36.6% | 38.7% | 39.5% |
| Operating Margin % | 20.6% | 17.4% | 18.0% | 25.0% | 28.3% | 30.7% | 32.7% | 30.3% | 27.1% | 34.8% | 35.5% | 35.9% |
| Net Margin % | 12.5% | 8.3% | 3.9% | 13.0% | 14.9% | 14.2% | 14.9% | 8.5% | 12.7% | -0.4% | -35.9% | -14.3% |
| ROE % | 31.0% | 15.5% | 27.7% | 47.9% | 49.9% | 34.6% | 28.3% | 17.5% | 30.3% | -0.9% | -220.4% | -562.6% |
| ROCE % | - | 24.5% | 23.5% | 31.3% | 28.3% | 20.6% | 18.8% | 19.2% | 18.6% | 18.7% | 24.2% | 32.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.60% | 5.36M | $372.44M |
| 2 | Vanguard Portfolio Management LLC | 6.91% | 2.38M | $165.02M |
| 3 | Vanguard Capital Management LLC | 4.57% | 1.57M | $109.08M |
| 4 | State Street Corporation | 4.36% | 1.50M | $103.96M |
| 5 | American Century Companies Inc | 3.70% | 1.27M | $88.24M |
| 6 | Wellington Management Group, LLP | 3.13% | 1.08M | $74.67M |
| 7 | Segall Bryant & Hamill, LLC | 3.07% | 1.05M | $73.22M |
| 8 | Millennium Management Llc | 2.89% | 992.05K | $68.88M |
| 9 | Brown Advisory Inc. | 2.83% | 974.11K | $67.63M |
| 10 | Royce & Associates LP | 2.74% | 940.42K | $65.29M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NGVT
A live webcast will feature Ingevity’s CEO and CFO on Sept. 10 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQSlFtTnE1TmYtdUZ1QkpxWmFkUVBEMGJhbmVyRm45SDdhTWVieDBkdlRIc1kwcTlSWTBpUGdiWTFwMnZrZ1lDTlg4MEpmTDBPaDhGOE13a25YX2RLMVRBQWJKclZlWTVzOHM4SE1nU2tJTl8zVWE4eUlja0VsS3JLZnVsOW9qOGI3UEtZM2…
Why You Should Add Ingevity Stock to Your Portfolio Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNdmotOUhIcVRGSmZsTGR0RlFMa3VlS09NZE9NOXE3dUI5Ulo2b1VCcjV1Qm1zNzdaOU9sSkV1Mkl3bGlkNzNDbVVuZEVGRFNuT01jUERsWm9VT24zREd0Vk1JcDhIRmYxN29Ud3RCaDl0NTFaeV9nVXVDckRWZTk4dWtMVzhLZTVfTTNFQm…
Ingevity (NGVT) Stock Looks Overvalued After A 29% Three Year Gain - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE9xTkZGcjVBZ0xvWk5SbHN6Z2l6TGFPcjdiMUU5MDZVdmVhN0RkUjVMZ29tbGUtMkNidXF1NFVrUTU4Nnd0R1E5Qm1RMlZOWWU5MHM5SHNyejE?oc=5" target="_blank">Ingevity (NGVT) Stock Looks Overvalued After A 2…
Ingevity (NGVT) Stock Looks Overvalued After A 29% Three Year Gain - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQeE1wNm5scGZNUkQ3QjV2T3lzdGtUc1JDNnVScnlaaWFqdk81dlRaMmQzeGcxX3lFWEdMd1lnWWh4V0JGbU1zeEh5dk9pU2FKbVFXalY3OWZldmowNEFHZXRVaHE2OXlCM2cyM3RyNnpvVXBJUDJKQlBTeU1veE1UZTlzQUJrdkdidzUxLW…
(NGVT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNRnRROTJGWG9qQ2E2MkZ0THVMRXNXNUc1VjZxaWtMYVpXcjY5dFY4d0xBdzBXaWhtMS1uTXNjRmhJekNKNHRvSk94WFdxX0FBbXo4LXp5WXoyN1JmeG5vYzdTQmJrUVloMGJEcUZ2aFFVOFVpcDlSNzBSSk1GV2l2aXV0QVNsU0d3blFUTU…
Insider Sale: SVP of $NGVT Sells 266 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNWkxWTUhOR1h4bHFCTFpDSkw0YV9ZNFlYNzZVRG5BVXNvYVh2SV9hUGJpS2l5N2JJWS1kSk5kNmZBOUU0RHNBZW4tclZzZ1o2NU02c08tVnFGX3c2Z2FyMUR4WW5ZWU1qQUpoRUxnTjNiX2tPcDVoazlmUzd2U3dvR2tSTm5CbWc?oc=5" …
NGVT — Frequently Asked Questions
What is the current share price of Ingevity Corporation (NGVT)?
As of 2026-09-07 16:24 PDT, Ingevity Corporation (NGVT) trades at $70.54 on NYSE. Its 52-week range is $46.20 to $77.87.
What is the market capitalisation of NGVT?
Ingevity Corporation (NGVT) has a market capitalisation of $2.43B on NYSE.
What is the P/E ratio of NGVT?
NGVT trades at a trailing price-to-earnings (P/E) ratio of 99.35. The industry average P/E is 22.37. Its price-to-book (P/B) ratio is 57.22.
What is the return on equity (ROE) of NGVT?
NGVT has a return on equity (ROE) of 30.07%. Its return on capital employed (ROCE) is 31.97%.
Is NGVT a good stock to buy?
This page provides a data-driven analysis of Ingevity Corporation (NGVT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.